Daniel W, Netter K J
Department of Pharmacology and Toxicology, University of Marburg, Medical School, Federal Republic of Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):234-40. doi: 10.1007/BF00166970.
The aim of this study was to investigate imipramine-induced alterations of cytochrome P-450 and to determine whether prolonged concomitant administration of imipramine and lithium results in a pharmacokinetic interaction. Male Wistar rats received imipramine (10 mg/kg i.p.) at 12 h intervals or lithium chloride (100 mg/kg in drinking water) or they were treated with the combination of these drugs for 2 weeks. The long term treatment with imipramine produced a very complex alteration of cytochrome P-450: imipramine increased the level of the cytochrome, but it decreased the rate of its own aromatic hydroxylation in position 2. The rate of N-demethylation in the side chain was not changed. Consequently, in the case of both hydroxylation and demethylation, calculated molecular activities were decreased to 48% and 70% respectively. This differential change in activities corresponded well to the observed decrease of absorption in difference spectra (type I) produced in microsomes by imipramine. Carbamazepine-induced type I difference spectra were also decreased by imipramine pretreatment, but to a lesser extent. In contrast, hexobarbital type I binding was increased by imipramine treatment while type II difference spectra produced by metyrapone were not affected. The preliminary SDS-PAGE analysis of cytochrome P-450 isoenzymes of control and imipramine treated rats showed that the investigated antidepressant markedly intensified a protein band at 50.11 kD while bands at 51.28 kD, 56.20 kD and 56.88 kD were less intensive. These results indicate that the alteration of cytochrome P-450 by imipramine treatment is not only of quantitative but also of qualitative character. Lithium alone given to rats affected neither the concentration of cytochrome P-450 in microsomal protein nor the rate of imipramine metabolism in vitro. Lithium given jointly with imipramine reduced imipramine-induced elevation of cytochrome P-450.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是调查丙咪嗪引起的细胞色素P - 450改变,并确定丙咪嗪与锂长期联合给药是否会导致药代动力学相互作用。雄性Wistar大鼠每隔12小时接受一次丙咪嗪(10 mg/kg腹腔注射)或氯化锂(饮用水中100 mg/kg),或者用这两种药物联合治疗2周。丙咪嗪的长期治疗产生了细胞色素P - 450非常复杂的改变:丙咪嗪增加了细胞色素的水平,但降低了其自身2位芳香羟基化的速率。侧链N - 去甲基化速率未改变。因此,在羟基化和去甲基化两种情况下,计算得出的分子活性分别降至48%和70%。活性的这种差异变化与丙咪嗪在微粒体中产生的差异光谱(I型)吸收减少相吻合。丙咪嗪预处理也降低了卡马西平诱导的I型差异光谱,但程度较小。相反,丙咪嗪治疗增加了己巴比妥I型结合,而甲吡酮产生的II型差异光谱未受影响。对对照大鼠和丙咪嗪处理大鼠的细胞色素P - 450同工酶进行的初步SDS - PAGE分析表明,所研究的抗抑郁药显著增强了50.11 kD处的蛋白条带,而51.28 kD、56.20 kD和56.88 kD处的条带强度较低。这些结果表明,丙咪嗪治疗引起的细胞色素P - 450改变不仅具有定量特征,还具有定性特征。单独给大鼠服用锂既不影响微粒体蛋白中细胞色素P - 450的浓度,也不影响体外丙咪嗪的代谢速率。锂与丙咪嗪联合给药降低了丙咪嗪引起的细胞色素P - 450升高。(摘要截短至250字)